文献速递瓣膜病与结构性心脏病

全国队列中经导管瓣膜治疗患者的衰弱及相关结局

Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort.
PubMed 文献 · Eur Heart J · 2019-01-01

基于美国Medicare 2016年数据库,纳入65岁及以上接受经导管二尖瓣修复或经导管主动脉瓣置换术(TAVR)的患者,用基于ICD-10索赔的医院衰弱风险评分识别衰弱。衰弱风险越高,1年全因死亡率越高,提示该评分可用于识别术后高危老年人。

要点

  • 医院衰弱风险评分可用于识别经导管瓣膜治疗后短期和长期死亡高危的老年患者。
  • 经导管二尖瓣修复患者1年死亡率随衰弱风险升高而升高(低12.8%、中29.7%、高40.9%)。
  • TAVR患者1年死亡率亦随衰弱风险升高而升高(低7.6%、中17.6%、高30.1%)。

核心结论

  • 在美國老年人群中,基于ICD-10索赔的医院衰弱风险评分可成功识别经导管瓣膜治疗后短期和长期死亡风险更高的个体。

研究设计与样本

  • 回顾性队列研究,使用2016年1月1日至2016年12月31日美国Centers for Medicare and Medicaid Services Medicare Provider and Review数据库。
  • 纳入65岁及以上、至少有一个经导管二尖瓣修复或TAVR操作编码的患者。
  • 采用基于ICD-10索赔的医院衰弱风险评分识别衰弱,主要结局为1年全因死亡。

主要发现

  • 经导管二尖瓣修复人群:低风险(评分<5)1903例(50.8%),中风险(评分5-15)1476例(39.4%),高风险(评分>15)367例(9.8%)。
  • 经导管二尖瓣修复1年死亡率:低风险12.8%、中风险29.7%、高风险40.9%(log rank P < 0.001)。
  • TAVR 1年死亡率:低风险7.6%、中风险17.6%、高风险30.1%(log rank P < 0.001)。

关键数值与推荐

  • 医院衰弱风险评分分组:低风险<5分,中风险5-15分,高风险>15分。
  • 主要结局为1年全因死亡率。

临床怎么用

  • 对准备接受经导管二尖瓣修复或TAVR的老年患者,可用医院衰弱风险评分进行风险分层并辅助预后沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We sought to identify the prevalence and related outcomes of frail individuals undergoing transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: Patients aged 65 and older were included in the study if they had at least one procedural code for transcatheter mitral valve repair or TAVR between 1 January 2016 and 31 December 2016 in the Centers for Medicare and Medicaid Services Medicare Provider and Review database. The Hospital Frailty Risk Score, an International Classification of Diseases, Tenth Revision (ICD-10) claims-based score, was used to identify frailty and the primary outcome was all-cause 1-year mortality. A total of 3746 (11.6%) patients underwent transcatheter mitral valve repair and 28 531 (88.4%) underwent TAVR. In the transcatheter mitral valve repair and TAVR populations, respectively, there were 1903 (50.8%) and 14 938 (52.4%) patients defined as low risk for frailty (score <5), 1476 (39.4%) and 11 268 (39.5%) defined as intermediate risk (score 5-15), and 367 (9.8%) and 2325 (8.1%) defined as high risk (score >15). One-year mortality was 12.8% in low-risk patients, 29.7% in intermediate-risk patients, and 40.9% in high-risk patients undergoing transcatheter mitral valve repair (log rank P < 0.001). In patients undergoing TAVR, 1-year mortality rates were 7.6% in low-risk patients, 17.6% in intermediate-risk patients, and 30.1% in high-risk patients (log rank P < 0.001). CONCLUSIONS: This study successfully identified individuals at greater risk of short- and long-term mortality after undergoing transcatheter valve therapies in an elderly population in the USA using the ICD-10 claims-based Hospital Frailty Risk Score.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kundi H, Popma JJ, Reynolds MR, et al. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J. 2019. PMID: 30977798. doi:10.1093/eurheartj/ehz187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。